Company Information
Industry 制造业
Company Introduction 贵州百灵企业集团制药股份有限公司是一家苗药研发、生产企业.其产品主要有咳化痰用药、感冒用药、心脑血管用药等中成药.公司按照拥有发明专利的苗药产品数量和2009年OTC类苗药产品销售额排名统计,位居全国第一,按照拥有药品批准文号的苗药产品数量和2009年单品种苗药销售额排名统计,公司位居全国第二。
Main Business 以苗药为主的中成药的生产、销售。主要从事止咳化痰用药、感冒用药及心脑血管用药系列中成药等产品的生产与销售,以及其他天然药物和化学药物的研究开发。
Legal Representative 姜伟
Top Executives
董事长:姜伟
董事:周义峰,陈培,牛民,姜勇
独立董事:胡坚,杨明,张洪武,晏国菀
Top 5 Shareholder
Shareholder name Nature Holding Date
姜伟限售股+流通A股17.55%30/09/2024
华创证券-证券行业支持民企发展系列之华创证券1号FOF单一资产管理计划-华创证券有限责任公司支持民企发展14号单一资产管理计划流通A股6.21%30/09/2024
华创证券-工商银行-华创证券有限责任公司支持民企发展1号集合资产管理计划流通A股5.33%30/09/2024
张明流通A股0.61%30/09/2024
张君鹏流通A股0.60%30/09/2024
Company Secretary 陈培
Solicitors 北斗星律师事务所
Auditors 天健正信会计师事务所有限公司
Tel No 0851-33415126
Fax No 0851-33412296
Website www.gzbl.com
Email niumin1804@126.com;chenzhibl@126.com;GZBLZQB@163.com
Company Address
Register: 贵州省安顺市经济技术开发区西航大道212号
Office: 贵州省安顺市经济技术开发区西航大道212号
Listing Date 03/06/2010
Shares Capital
Shares Capital: 1,397,598,400
Total A Share: 1,397,598,400
Listed A Share: 1,213,214,512
Non-tradable A Share: 184,383,888
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -0.300
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 2.489
Market Capitalization(RMB) 4.889B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.